4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C

John G. McHutchison, Gregory T. Everson, Stuart C. Gordon, +4

Journal of Hepatology

A Phase 2HepatologyHepatitis CViral HepatitisAntiviral Drug Development +7

11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS

J.-P. Bronowicki, Mitchell Davis, S. Flamm, +15

Journal of Hepatology

In Prior Peginterferon/ribavirinAntiviral TherapyVirologyPharmacotherapyAntiviral Drug +2

2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

E. Läwitz, M. Rodriquez-Torres, Vinod K. Rustgi, +6

Journal of Hepatology

Viral HepatitisImmunologyAntiviral Drug DevelopmentHepatitisVirology +5

[786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C

John G. McHutchison, Gregory T. Everson, S. Gordon, +4

Journal of Hepatology

A Phase 2Study Of TelaprevirHepatitis CViral HepatitisAntiviral Drug Development +6

Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens

Alessandra Mangia, E. Läwitz, Edward Gane, +13

Journal of Hepatology

Long-term Follow-upHepatologyHepatitis CViral HepatitisAntiviral Therapy +9

113 A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection

V. Rustgi, D. Nelson, Vijayan Balan, +13

Journal of Hepatology

Dose-escalation StudyA Phase 2HepatologyViral HepatitisAntiviral Drug Development +6

Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial

A. Muir, Z. Goodman, Carlos Emílio Levy, +13

Journal of Hepatology

AllergyPhase 2BGastroenterologyPlacebo-controlled TrialCholangiopathies +1

730 Early viral response to CPG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response

John G. McHutchison, R. Chalib, E. Tawitz, +8

Journal of Hepatology

Viral PersistenceViral HepatitisPrior Relapse ResponseImmunologyEarly Viral Response +8

Diagnostic value of cerebrospinal fluid myelin basic protein in patients with neurological illness.

L. Davies, J. G. McLeod, A. Muir, +1

PubMed

Neurological DisorderClinical NeurologyDiagnostic ValueSocial SciencesNeurobiology Of Disease +16

Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis

A. Sanyal, S. Harrison, Vlad Ratziu, +13

Journal of Hepatology

InflammationMetabolic SyndromeMetabolic Associated SteatohepatitisFibrosisHepatology +13